Skip to main content

NHS: Drugs

Question for Department of Health and Social Care

UIN 17128, tabled on 13 June 2022

To ask the Secretary of State for Health and Social Care, what role the cost of medication plays in the Government's decision to procure (a) Evusheld, (b) Beblitovimab and (c) other drugs.

This answer is the replacement for a previous holding answer.

Answered on

21 June 2022

COVID-19 treatments must be effective against the variants currently circulating in the United Kingdom and receive marketing authorisation prior to procurement. While Evusheld was granted conditional marketing authorisation in March 2022, the Medicines and Healthcare products Regulatory Agency raised uncertainty over the dose needed for protection against the Omicron variant. The UK Health Security Agency is currently undertaking further testing on Evusheld’s efficacy against the Omicron variant. The data for Bebtelovimab shows efficacy against the currently circulating Omicron variants, although the treatment has not received marketing authorisation in the UK.

There is currently no funding allocated for these treatments. However, funding for additional procurement of novel treatments is considered on a case-by-case basis, as guided by clinical need and subject to business cases and due process.

Named day
Named day questions only occur in the House of Commons. The MP tabling the question specifies the date on which they should receive an answer. MPs may not table more than five named day questions on a single day.